title: T-cell-receptor dose and the time of treatment during murine retrovirus infection for maintenance of immune function.
abstract: C57BL/6 mice were injected with different doses of human T-cell receptor (TCR) V beta 8.1 CDR1 peptide at different times after murine retrovirus (LP-BM5) infection. Injection with TCR V beta 8.1 CDR1 peptide largely prevented the retrovirus-induced reduction in B- and T-cell proliferation, and T-helper 1 (Th1) cytokines [interleukin-2 (IL-2) and interferon-gamma (IFN-gamma)] secretion. It also suppressed T-helper 2 (Th2) cytokines (IL-6 and IL-10) production, which was stimulated by retrovirus infection. These effects were accomplished using at least 100 micrograms of peptide per mouse and the most effective dose of peptide had to be given within 4 weeks after retrovirus infection. Immunization with doses above 100 micrograms/mouse as long as 4 weeks postinfection maintained natural killer (NK) cell activity during retrovirus infection. Reducing the dose of peptide or delaying it until the disease progressed towards early murine acquired immune deficiency syndrome (AIDS) allowed development of immune dysfunction. These studies provide data suggesting that immune dysfunction, induced by murine retrovirus infection, was largely prevented by TCR V beta CDR1 peptide injection.
authors.affiliation: Department of Family and Community Medicine, University of Arizona, Tucson 85724, USA.
authors.forename: B
authors.initials: B
authors.lastname: Liang
authors.forename: S
authors.initials: S
authors.lastname: Ardestani
authors.forename: J J
authors.initials: JJ
authors.lastname: Marchalonis
authors.forename: R R
authors.initials: RR
authors.lastname: Watson
mesh_terms: D000276:Adjuvants, Immunologic; D000818:Animals; D001835:Body Weight; D018929:Cell Culture Techniques; D016207:Cytokines / Q000096:biosynthesis; D003602:Cytotoxicity, Immunologic; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D007111:Immunity, Cellular; D007115:Immunization Schedule; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D016183:Murine Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D016693:Receptors, Antigen, T-Cell, alpha-beta; D013154:Spleen / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D011948:Receptors, Antigen, T-Cell; D016693:Receptors, Antigen, T-Cell, alpha-beta; C075784:T cell receptor Vbeta8